Irorain 500mg Injection contains Ferric Carboxymaltose, a parenteral iron preparation indicated for the treatment of iron deficiency anemia when oral iron preparations are ineffective or cannot be used. This formulation provides a controlled release of iron, facilitating rapid replenishment of iron stores and correction of anemia. Irorain is particularly useful in patients with chronic kidney disease, inflammatory bowel disease, or those undergoing chemotherapy, where iron absorption may be impaired. The injection is administered intravenously, allowing for higher doses of iron to be delivered safely in a single session, minimizing the need for multiple administrations. Ferric Carboxymaltose has a favorable safety profile, with a low risk of hypersensitivity reactions compared to older intravenous iron formulations. Common adverse effects may include transient headache, nausea, dizziness, and injection site reactions. Prior to administration, patients should be evaluated for iron overload and hypersensitivity to iron products. Monitoring of hemoglobin levels and iron indices is recommended to assess therapeutic response and avoid iron overload. Irorain 500mg Injection should be administered under medical supervision with appropriate resuscitation facilities available. This product offers an effective and convenient option for rapid iron repletion in patients with iron deficiency anemia.